Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115826

Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.

K Takahashi, T M Nammour, M Fukunaga, J Ebert, J D Morrow, L J Roberts 2nd, R L Hoover, and K F Badr

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Takahashi, K. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Nammour, T. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Fukunaga, M. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Ebert, J. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Morrow, J. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Roberts, L. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Hoover, R. in: PubMed | Google Scholar

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Find articles by Badr, K. in: PubMed | Google Scholar

Published July 1, 1992 - More info

Published in Volume 90, Issue 1 on July 1, 1992
J Clin Invest. 1992;90(1):136–141. https://doi.org/10.1172/JCI115826.
© 1992 The American Society for Clinical Investigation
Published July 1, 1992 - Version history
View PDF
Abstract

8-epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) and related compounds are novel prostanoid produced by a noncyclooxygenase mechanism involving lipid peroxidation. Renal ischemia-reperfusion injury increased urinary excretion of these compounds by 300% over baseline level. Intrarenal arterial infusion at 0.5, 1, and 2 micrograms/kg per min induced dose-dependent reductions in glomerular filtration rate (GFR) and renal plasma flow, with renal function ceasing at the highest dose. Micropuncture measurements (0.5 microgram/kg per min) revealed a predominant increase in afferent resistance, resulting in a decrease in transcapillary hydraulic pressure difference, and leading to reductions in single nephron GFR and plasma flow. These changes were completely abolished or reversed by a TxA2 receptor antagonist, SQ 29,548. Competitive radioligand binding studies demonstrated that 8-epi-PGF2 alpha is a potent competitor for [3H]SQ 29,548 binding to rat renal arterial smooth muscle cells (RASM) in culture. Furthermore, addition of 8-epi-PGF2 alpha to RASM or isolated glomeruli was not associated with stimulation of arachidonate cyclooxygenase products. Therefore, 8-epi-PGF2 alpha is a potent preglomerular vasoconstrictor acting principally through TxA2 receptor activation. These findings may explain, in part, the beneficial effects of antioxidant therapy and TxA2 antagonism observed in numerous models of renal injury induced by lipid peroxidation.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 136
page 136
icon of scanned page 137
page 137
icon of scanned page 138
page 138
icon of scanned page 139
page 139
icon of scanned page 140
page 140
icon of scanned page 141
page 141
Version history
  • Version 1 (July 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts